Acyclovir (Zovirax)

Acyclovir, commonly known by the brand name Zovirax, is a nucleoside analog antiviral medication that has gained important applications in equine medicine for the treatment of herpesvirus infections. While originally developed and FDA-approved for human use against herpes simplex and varicella-zoster viruses, acyclovir has demonstrated activity against equine herpesviruses and is used extra-label in horses under veterinary supervision. This medication represents one of the few antiviral options available for treating viral infections in horses, filling a critical therapeutic gap in equine medicine.

The mechanism of action of acyclovir involves selective inhibition of viral DNA synthesis through a multistep process that takes advantage of virus-specific enzymes. The drug is initially phosphorylated by viral thymidine kinase, an enzyme present in infected cells but not in uninfected cells. This selective activation means that acyclovir preferentially concentrates in virus-infected cells, providing targeted antiviral activity while minimizing effects on healthy tissues. Once fully phosphorylated to its active triphosphate form, acyclovir is incorporated into viral DNA and causes chain termination, halting viral replication.

Acyclovir is available in several formulations that have been adapted for use in horses, including oral tablets, oral suspension, and injectable preparations for intravenous administration. The oral formulations are most commonly used in ambulatory practice, though bioavailability in horses is limited compared to other species. Intravenous administration provides more predictable drug levels and is preferred in severe cases or when rapid achievement of therapeutic concentrations is critical. Some horses may receive topical acyclovir preparations for localized herpesvirus lesions, though systemic therapy is typically the primary treatment approach.

The use of acyclovir in horses requires veterinary supervision due to its extra-label status, the need for accurate diagnosis of herpesvirus infection, and the importance of appropriate dosing for this species. Equine herpesviruses pose significant challenges to horse health and welfare, and effective antiviral therapy can be an important component of disease management. The decision to use acyclovir should be based on confirmed or strongly suspected herpesvirus infection, as antiviral medications are not effective against bacterial or other non-viral pathogens.

The primary indication for acyclovir in horses is the treatment of infections caused by equine herpesviruses, particularly Equine Herpesvirus-1 and Equine Herpesvirus-4. These viruses are ubiquitous in horse populations worldwide and can cause a spectrum of clinical disease ranging from mild respiratory illness to severe neurological disease and abortion in pregnant mares. Acyclovir's antiviral activity against these pathogens provides a therapeutic option for managing clinical disease and potentially reducing viral shedding, though the medication cannot eliminate latent herpesvirus infection.

Equine Herpesvirus-1 neurological disease, often referred to as Equine Herpesvirus Myeloencephalopathy, represents one of the most serious manifestations of EHV infection and a key indication for acyclovir therapy. This condition causes inflammation and damage to the spinal cord and brain, resulting in neurological signs that can range from mild ataxia and weakness to complete recumbency and bladder dysfunction. Early initiation of antiviral therapy, ideally at the first signs of neurological involvement, may help limit disease progression and improve outcomes. Treatment is most effective when started early in the disease course before extensive neurological damage has occurred.

Respiratory disease caused by EHV-1 and EHV-4 may also be treated with acyclovir, particularly in cases where clinical signs are significant or when preventing spread to other horses is a priority. Young horses experiencing their first exposure to equine herpesviruses commonly develop respiratory illness characterized by fever, nasal discharge, and cough. While many cases resolve with supportive care alone, antiviral therapy may be considered in more severe cases or during outbreak situations where reducing viral shedding is important for disease control.

Pregnant mares exposed to or infected with EHV-1 represent another important treatment consideration, as abortion storms can have devastating economic and emotional impacts on breeding operations. Acyclovir treatment of exposed or early-stage infected mares may help prevent fetal infection and subsequent abortion, though outcomes are variable and dependent on timing of intervention. The decision to treat pregnant mares should be made in consultation with a veterinarian experienced in equine reproduction and infectious disease management.

The use of acyclovir for herpesvirus infections in horses should be guided by diagnostic confirmation when possible, as clinical signs of herpesvirus infection can overlap with other respiratory and neurological conditions. Polymerase chain reaction testing of nasal secretions, blood, or cerebrospinal fluid can help confirm active herpesvirus infection. However, in outbreak situations or when clinical presentation is highly suggestive, treatment may be initiated empirically while awaiting diagnostic results, as early intervention is associated with better outcomes.

Dosing of acyclovir in horses is determined by the veterinarian based on the individual patient's weight, clinical condition, route of administration, and the specific formulation being used. Because acyclovir is not FDA-approved for equine use, there is no standardized equine dosing regimen, and protocols may vary among practitioners based on clinical experience and available research. Accurate body weight measurement is essential for calculating appropriate doses, as both underdosing (potentially ineffective) and overdosing (increased risk of adverse effects) should be avoided.

Oral acyclovir administration in horses faces challenges related to limited bioavailability in this species. Studies have shown that oral bioavailability of acyclovir in horses is considerably lower than in humans, meaning that higher doses or more frequent administration may be needed to achieve therapeutic blood levels. Oral dosing is typically administered multiple times daily, with three to five times daily dosing being common recommendations. Despite the bioavailability limitations, oral acyclovir remains widely used due to practical advantages for outpatient treatment and the challenges associated with prolonged intravenous therapy.

Intravenous acyclovir administration provides more predictable drug levels and is often preferred in severe cases, particularly those involving neurological disease. IV therapy allows rapid achievement of therapeutic concentrations and ensures consistent drug delivery regardless of gastrointestinal absorption variables. However, IV administration requires either hospitalization or very dedicated owners capable of maintaining IV access and administering multiple daily treatments. The risk of thrombophlebitis and other catheter-related complications increases with prolonged IV therapy.

Treatment duration for equine herpesvirus infections typically ranges from one to three weeks depending on clinical response and disease severity. Neurological cases may require longer treatment courses, particularly if clinical improvement is slow. The veterinarian will determine the appropriate treatment duration based on ongoing assessment of the patient's condition. Premature discontinuation of therapy could allow viral resurgence, while unnecessarily prolonged treatment increases the risk of adverse effects and adds to treatment costs.

Administration of oral acyclovir tablets or suspension can be accomplished by mixing the medication with a small amount of palatable carrier such as applesauce or molasses and administering via oral syringe, or by placing tablets directly in the mouth. Ensuring complete dose consumption is important, as partial dosing could result in subtherapeutic drug levels. The medication is typically given with or without food, though some protocols may specify particular administration conditions.

Missed doses should be addressed according to veterinary guidance, generally by administering the missed dose as soon as remembered unless the next scheduled dose is approaching. Doubling doses to compensate for missed administration should be avoided. Maintaining consistent dosing intervals is important for keeping drug levels in the therapeutic range, particularly given the multiple daily dosing typically required for acyclovir in horses.

Acyclovir is generally well tolerated in horses when administered at appropriate doses under veterinary supervision. The medication's selective mechanism of action, which preferentially targets virus-infected cells, contributes to its favorable safety profile. However, adverse effects can occur, particularly with high doses or prolonged treatment, and monitoring for signs of drug-related problems is an important component of therapy management.

Gastrointestinal side effects represent the most commonly observed adverse reactions to oral acyclovir in horses. Decreased appetite, soft stool, or mild diarrhea may occur during treatment. These effects are usually mild and may resolve with continued treatment as the horse adjusts to the medication. However, significant appetite reduction or persistent gastrointestinal disturbance warrants veterinary attention, as maintaining adequate nutrition and hydration is important for horses recovering from viral infection. In some cases, dose adjustment or temporary treatment interruption may be needed.

Renal effects are an important consideration with acyclovir therapy, as the drug is primarily eliminated through the kidneys. Acyclovir can crystallize in renal tubules, particularly when dehydration is present or when high doses are administered rapidly via the intravenous route. Maintaining adequate hydration throughout treatment helps minimize the risk of renal complications. Horses receiving acyclovir, especially by the intravenous route, should have consistent access to fresh water, and monitoring for signs of reduced urine output or other evidence of renal dysfunction is prudent.

Neurological side effects, though uncommon, have been reported with acyclovir use and may include behavioral changes, tremors, or altered mentation. These effects are more commonly associated with high doses or impaired renal function leading to drug accumulation. Any unexpected neurological changes during treatment should be reported to the veterinarian promptly, though it is important to distinguish potential drug effects from progression of underlying herpesvirus-related neurological disease.

Local reactions at injection sites may occur with intravenous administration, including phlebitis and tissue irritation. Proper IV catheter care and monitoring for signs of catheter-related complications are important components of managing horses receiving IV acyclovir. Extravasation of acyclovir solution can cause significant tissue damage, and careful attention to catheter placement and function helps prevent this complication. Any signs of swelling, heat, pain, or discharge at the catheter site should prompt veterinary evaluation.

Acyclovir is contraindicated in horses with known hypersensitivity to the medication or to related antiviral compounds such as valacyclovir, famciclovir, or ganciclovir. Previous adverse reactions to any of these medications should be disclosed to the veterinarian before treatment initiation, as cross-reactivity may occur among structurally related antiviral agents. While true allergic reactions to acyclovir are uncommon, any history of drug hypersensitivity reactions warrants careful consideration of treatment alternatives.

Significant renal impairment represents an important contraindication or precaution for acyclovir use in horses. The drug is primarily eliminated through the kidneys, and impaired renal function can lead to drug accumulation and increased risk of adverse effects, including nephrotoxicity. Horses with known kidney disease, dehydration, or conditions predisposing to renal dysfunction should be carefully evaluated before acyclovir therapy is initiated. If treatment is deemed necessary in horses with compromised renal function, dose reduction and enhanced monitoring may be required.

The safety of acyclovir in pregnant mares has not been fully established, though the medication has been used in this population for treatment of EHV-1 infection to prevent abortion. Human studies have not demonstrated significant teratogenic risk, and the potential benefits of preventing herpesvirus-induced abortion may outweigh theoretical risks in many situations. However, the decision to treat pregnant mares should be made on a case-by-case basis with careful consideration of the specific clinical circumstances. Breeding stallions present similar considerations, as the effects of acyclovir on fertility have not been extensively studied in horses.

Dehydrated horses or those unable to maintain adequate fluid intake face increased risk of renal complications with acyclovir therapy. Ensuring adequate hydration before initiating treatment and maintaining hydration throughout the treatment course is essential. Horses that are severely ill, not drinking, or otherwise unable to maintain normal hydration status may require intravenous fluid support concurrent with acyclovir therapy. The additional management demands of maintaining hydration should be factored into treatment planning.

Drug interactions with acyclovir in horses are not extensively documented, but several potential interactions warrant consideration when planning treatment protocols. The most clinically significant interactions involve drugs that affect renal function or that are also eliminated primarily through the kidneys, as competition for renal excretion pathways or additive nephrotoxic effects could occur.

Concurrent administration of other potentially nephrotoxic medications with acyclovir should be approached cautiously. Non-steroidal anti-inflammatory drugs, commonly used in horses for pain and fever management, can affect renal blood flow and potentially increase the risk of renal complications when combined with acyclovir. While NSAID use may be necessary in horses with fever or discomfort associated with herpesvirus infection, careful attention to hydration status and monitoring for signs of renal dysfunction is important. Aminoglycoside antibiotics, though less commonly used, also pose nephrotoxic risks that could be additive with acyclovir.

Probenecid and other drugs that compete for renal tubular secretion could potentially increase acyclovir blood levels by reducing its elimination. While this interaction is better characterized in humans than horses, awareness of this potential effect is appropriate when multiple medications are being administered. Conversely, drugs that increase renal blood flow or urine output could theoretically enhance acyclovir elimination and potentially reduce efficacy, though this interaction is not well documented in horses.

Immunosuppressive medications may have complex interactions with antiviral therapy. Horses receiving corticosteroids or other immunosuppressive treatments may have altered susceptibility to viral infections and potentially different responses to antiviral therapy. The use of immunosuppressive drugs during active herpesvirus infection is generally discouraged due to concerns about enhanced viral replication and disease progression. However, some horses may have concurrent conditions requiring immunosuppressive therapy, and management of these cases requires careful veterinary judgment.

Competition horses receiving acyclovir face regulatory considerations regarding prohibited substances and withdrawal times. Acyclovir is not a commonly tested compound in equine competition, but veterinarians should be consulted regarding any medication use in horses intended for competition. The extra-label nature of acyclovir use in horses means that established withdrawal time recommendations may not be available, and conservative approaches to competition timing are warranted.

Monitoring during acyclovir therapy should include assessment of clinical response, hydration status, and renal function. Baseline blood work including kidney values may be recommended before initiating treatment, with periodic monitoring during prolonged therapy. For horses receiving intravenous acyclovir, daily assessment of catheter sites and overall patient status is essential. Clinical improvement in herpesvirus-related symptoms provides important feedback about treatment efficacy, though response may be gradual, particularly in neurological cases.

Special populations require additional consideration when planning acyclovir therapy. Foals and young horses, while certainly susceptible to herpesvirus infections, may have different pharmacokinetics compared to adult horses, and dosing should be carefully determined. Geriatric horses, particularly those with age-related decline in renal function, may require dose adjustments or enhanced monitoring. Horses with concurrent illness or those receiving multiple medications need comprehensive treatment planning that accounts for all aspects of their medical management.

Competition horses present unique considerations due to medication regulations governing equine sports. While acyclovir is not a commonly restricted substance in the same way as performance-modifying drugs, its presence could potentially be detected, and competition rules should be reviewed. Most horses requiring acyclovir treatment for active herpesvirus infection would not be competing due to illness and quarantine requirements, but planning for return to competition should include appropriate medication withdrawal considerations. Veterinary guidance specific to the horse's competitive activities is important.

Biosecurity considerations during treatment of herpesvirus-infected horses extend beyond pharmaceutical management. Horses with active herpesvirus infections can shed virus to susceptible herdmates, and appropriate isolation protocols should be implemented. Treatment with acyclovir may reduce viral shedding, but treated horses should still be managed as potentially infectious until the appropriate time period has elapsed. Coordination with facility management, attending veterinarians, and relevant regulatory authorities is important during herpesvirus outbreaks.

Long-term use of acyclovir in horses is not typically necessary, as treatment courses are generally limited to the acute phase of herpesvirus infection. However, some horses may require extended treatment for severe neurological disease or may be treated prophylactically during outbreak situations. Prolonged therapy increases cumulative exposure and the potential for adverse effects, particularly renal complications. The duration of treatment should be regularly reassessed, and therapy should continue only as long as clinically indicated.

Proper storage of acyclovir products maintains medication stability and ensures therapeutic efficacy throughout the treatment period. Oral formulations including tablets and suspensions should be stored at controlled room temperature, typically between 59°F and 77°F (15°C to 25°C), protected from excessive heat, freezing, moisture, and direct light. The original container should be kept tightly closed when not in use. Oral suspensions should be shaken well before each use to ensure uniform distribution of the medication.

Injectable acyclovir preparations require specific storage and handling according to the manufacturer's instructions. Reconstituted solutions typically have limited stability and should be used within the timeframe specified or discarded. Some injectable formulations require refrigeration after reconstitution, while others maintain stability at room temperature for limited periods. Attention to these requirements is essential for ensuring that administered medication retains its full potency. Healthcare providers administering IV acyclovir should be familiar with proper reconstitution and administration procedures.

Human exposure considerations apply to acyclovir handling, though the medication is not classified as highly hazardous. Basic precautions including handwashing after handling the medication and avoiding unnecessary direct contact are appropriate. Individuals who are immunocompromised or pregnant should exercise additional caution, consistent with general medication handling recommendations. Accidental ingestion of acyclovir by humans, while unlikely to cause serious harm, should prompt consultation with a physician. Disposal of unused or expired acyclovir should follow local guidelines for pharmaceutical waste. Medications should not be disposed of in ways that could allow access by children, animals, or contaminate water supplies. Many pharmacies and veterinary clinics offer medication take-back programs for safe disposal of unused products.

Draft horses and large breeds require appropriate dose scaling when acyclovir treatment is indicated. The larger body mass of draft horses means that total drug quantities will be correspondingly higher, which may have cost implications given the expense of antiviral medications. Accurate weight determination is important for proper dosing, and the challenges of weighing large horses should be addressed through use of appropriate weight tapes or access to scales capable of accommodating draft breeds. The pharmacokinetics of acyclovir in draft horses specifically have not been extensively studied, and dosing is generally extrapolated from experience in lighter breeds.

Light horse breeds and warmbloods represent the population in which most experience with equine acyclovir use has been accumulated. These breeds are commonly affected by herpesvirus outbreaks, particularly in performance horse populations where stress and congregation at events may facilitate disease transmission. Treatment protocols developed for these breeds generally serve as the reference standard for acyclovir use across horse populations. Breed-specific susceptibility to equine herpesviruses is not well characterized, but management factors such as travel, competition stress, and herd mixing likely play larger roles than breed genetics.

Ponies and miniature horses require careful dose calculation when acyclovir treatment is needed. The smaller body mass of these breeds means that medication volumes will be correspondingly smaller, and accurate dosing is essential to avoid both underdosing and overdosing. Miniature horses in particular require precise calculations, and compounding of appropriate dosage forms may be helpful for ensuring accurate administration. The bioavailability and pharmacokinetics of acyclovir in small equines have not been specifically studied.

Breed-specific genetic factors are not known to significantly affect acyclovir response or safety in horses. However, individual variation in drug metabolism exists across all breeds, and monitoring for both efficacy and adverse effects remains important regardless of breed. Breeds with known predispositions to immune system dysfunction or other health conditions should be managed according to their individual needs. The immune status of the horse may influence the outcome of herpesvirus infection and response to treatment, though breed-specific immune characteristics are not a primary consideration in treatment planning.

Valacyclovir represents the most closely related medication to acyclovir and offers potential advantages for equine use. Valacyclovir is a prodrug that is converted to acyclovir after absorption, providing improved oral bioavailability compared to acyclovir itself. Studies in horses have demonstrated that valacyclovir achieves higher blood levels of acyclovir than equivalent oral doses of the parent compound. This improved bioavailability may translate to better efficacy for oral treatment, making valacyclovir an increasingly popular choice for treating equine herpesvirus infections. However, valacyclovir is generally more expensive than acyclovir, which may influence treatment decisions.

Ganciclovir is another antiviral in the same pharmacological class that has been used in horses, though less commonly than acyclovir or valacyclovir. Ganciclovir has broader antiviral activity and is particularly effective against cytomegalovirus infections, though its relevance to equine herpesviruses is less well established. The toxicity profile of ganciclovir, including bone marrow suppression, generally makes it a second-line option reserved for cases where other antivirals are ineffective or contraindicated.

Supportive care medications complement antiviral therapy in managing equine herpesvirus infections. Anti-inflammatory medications may be used to manage fever and inflammation, though their use should be balanced against potential effects on immune function. Intravenous fluid therapy supports hydration in horses with decreased water intake and helps minimize the risk of renal complications from antiviral medications. Neurological cases may require additional supportive measures including bladder management, physical support for ataxic horses, and nursing care for recumbent patients. Comprehensive management of herpesvirus infections typically extends well beyond antiviral medication alone, and veterinary guidance is essential for coordinating all aspects of treatment. The decision to substitute one antiviral for another or to add complementary therapies should always be made in consultation with the attending veterinarian.